Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout

Submitted by admin on October 24, 2021 - 10:40pm
Source: 
Fierce Pharma
News Tags: 
Bristol Myers Squibb
Acceleron
M&A
Aurinia Pharmaceuticals
Headline: 
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout
snippet: 

It wasn't long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn't come together, and the biotech eventually sold to Merck for $11.5 billion. Now, BMS has its eyes on another target, Bloomberg reports.

Do Not Allow Advertisers to Use My Personal information